New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
07:34 EDTACRXAcelRx says Phase 3 trials continue to progress
AcelRx Pharmaceuticals announced continuing progress on its two remaining Phase 3 trials of the Sufentanil NanoTab PCA System being studied in post-operative pain. The first of those studies in patients after major abdominal surgery completed the last patient earlier this quarter, and is expected to provide data later this quarter. The second study, in patients after major orthopedic surgery, continues to enroll patients, with the last patient expected to enroll around the end of the first quarter of 2013, and data expected in the second quarter.  A New Drug Application submission for the NanoTab System remains on track for the third quarter of 2013.  In addition, a Phase 2 clinical trial with ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, has completed dosing and results from this study are expected to be available in the second quarter of 2013, the company said.
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 13, 2014
07:08 EDTACRXAcelRx to present positive efficacy results in Phase 3 trial of Zalviso
AcelRx Pharmaceuticals will present safety and efficacy data from a Phase 3 pivotal trial evaluating the Zalviso sufentanil sublingual tablet system for the treatment of moderate-to-severe acute pain following joint replacement surgery at the American Society of Regional Anesthesia and Pain Medicine 13th Annual Pain Medicine Meeting on November 13th to November 16th in San Francisco. Data from the sublingual sufentanil tablet system development program highlights efficacy across various demographic populations
November 11, 2014
10:20 EDTACRXHigh option volume stocks
High option volume stocks: RLGY TWC LITB SPM ACRX JWN OCR CALL CST ERIC
November 10, 2014
16:16 EDTACRXAcelRx sees FY14 R&D expenses $25M-$27M
Subscribe for More Information
16:15 EDTACRXAcelRx reports Q3 EPS (13c), consensus (22c)
Reports Q3 revenue $4.83M, consensus $4.43M.
07:12 EDTACRXAcelRx receives ISO certification of its quality management system
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use